TNYA logo

TENAYA THERAPEUTICS INC

TNYANASDAQ
🏆 #3965 by market capEarnings Nov 9US Equity
$0.60▲ $0.01 (+1.57%)
Market closed · at close
🔔
Track TNYA
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.6%
7d▼ 9.9%
14d▼ 9.5%
30d▼ 13.6%
ytd▼ 15.4%
1y▼ 63.4%
🏦Market Cap
$129M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
263.7%
High
💵FCF Margin
-5380.8%
Thin
⚖️P/S Ratio
95.9x
Expensive
Otter Score
60
Fair

Trading Snapshot

Day Range
$0.59 – $0.60
52-Week Range
$0.53 – $2.35
Volume
$3.73B
Avg Volume
$2.88B
Shares Outstanding
217.0M
Next Earnings
Oct 30, 2026

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$1M
P/E Ratio
-1.1
P/S Ratio
95.9x
EPS (TTM)
$-0.47
Dividend Yield
0.00%
Dilution (1yr)
+77.0%

Why Investors Own TNYA

  • ✓High-growth profile — revenue up +10.2% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 36% gross margin and 24% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

TNYA logo

TENAYA THERAPEUTICS INC

TNYA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$93M▼ −19.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$69M▼ −24.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
153.0M▲ +77.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$90M▲ +$99M YoY
StockOtter · stockotter.space

About TENAYA THERAPEUTICS INC

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Ratings

ⓘ
Consensus
Buy
13 analysts
Strong Buy4
Buy8
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
CNBC·2h ago

TENAYA THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift TNYA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

TENAYA THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.